Is Inavolisib currently on the market in the country?

Inavolisib (Inavolisib) is a new PI3Kα inhibitor, mainly used to treat hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer carrying PIK3CA mutations. The drug is highly selective and can precisely target the PIK3CA mutation pathway to block the proliferation and survival signals of cancer cells, thereby achieving anti-tumor effects. After verification in multiple international clinical trials, inaliside has shown significant advantages in prolonging progression-free survival (PFS) and has become a highly anticipated targeted therapy drug in recent years.

At present, inalise has been officially approved for marketing by the National Medical Products Administration (NMPA) in mainland China. It is mainly used in combined endocrine therapy programs for breast cancer patients with PIK3CA mutations. This marks a key step in the field of PI3K targeted therapy in China. However, due to the short time it has been on the market, the drug has not yet been included in the national medical insurance catalog. Therefore, patients are temporarily unable to enjoy the medical insurance reimbursement policy, and the required treatment costs must be fully paid out of pocket, which puts great financial pressure.

In terms of price, the common specifications of inaliset in the Chinese market include 3mg7tablets4 boards and 9mg7tables4boards. The cost of a complete course of treatment is approximately RMB 30,000. In contrast, in overseas markets such as the United States or EU countries, the price of the drug is higher. The price of a box of drugs may range from more than 200,000 yuan, which is also affected by regional pricing policies and exchange rate fluctuations. Currently, there are no generic drugs on the market globally, so the main purchasing sources available to patients are original drugs.

Overall, the launch of inalise has brought new treatment hope to some breast cancer patients, but high drug prices and lack of medical insurance are still practical problems that hinder its widespread use. It is recommended that patients determine the suitability under a doctor's evaluation and choose a reasonable medication route based on their own economic conditions. At the same time, with the in-depth marketing promotion and policy evaluation, the drug is expected to be included in the medical insurance negotiation list in the future, further improving its accessibility and patient treatment benefits.

Reference materials:https://www.drugs.com/